Segmental Reporting (Tables)

6 Months Ended

Jun. 30, 2015

Segment Reporting [Abstract]

Schedule of Segment Revenue from Major Products

6 months to	June 30,	June 30,
	2015	2014
	$’M	$’M
	___________	___________
VYVANSE	841.6	710.7
LIALDA/MEZAVANT	306.4	272.5
CINRYZE	286.9	215.5
ELAPRASE	271.5	280.7
REPLAGAL	214.4	244.8
FIRAZYR	196.6	163.9
ADDERALL XR	181.7	184.9
VPRIV	171.1	176.6
PENTASA	145.0	135.5
FOSRENOL	89.2	88.1
GATTEX/REVESTIVE	52.2	-
XAGRID	48.1	55.0
INTUNIV	26.9	182.3
NATPARA	5.9	-
Other product sales	61.9	67.2
	____________	____________
Total product sales	2,899.4	2,777.7
	____________	____________